SSAs are known to inhibit pancreatic secretion of insulin and glucagon, promoting the development of metabolic alterations in euglycemic patients, and aggravating the already partially impaired pancreatic function in patients with IGM or DM. The gene discussed is INS; the disease is diabetes mellitus.